Table 2.
T2DM | CAD | |||||||
---|---|---|---|---|---|---|---|---|
Method | N (SNPs) * | OR (95% CI) | p-Value | N (SNPs) † | OR (95% CI) | p-Value | ||
D6D | instruments from FADS | IVW | 6 | 1.08 (1.06–1.09) | <0.001 | 6 | 1.06 (1.02–1.11) | 0.008 |
MVIVW | 10 | 1.03 (0.94–1.12) | 0.528 | 10 | 1.00 (0.93–1.07) | 0.971 | ||
MVIVW ‡ | 10 | 1.03 (0.99–1.16) | 10 | 1.01 (0.91–1.12) | ||||
instruments from FADS and genome-wide hits | MVIVW | 12 | 1.03 (0.95–1.10) | 0.514 | 12 | 1.00 (0.95–1.06) | 0.907 | |
MVIVW ‡ | 12 | 1.01 (0.94–1.10) | 12 | 1.00 (0.96–1.15) | ||||
D5D | instruments from FADS | IVW | 9 | 1.03 (1.01–1.04) | <0.001 | 9 | 1.03 (1.01–1.05) | 0.017 |
MVIVW | 10 | 1.00 (0.96–1.04) | 0.824 | 10 | 1.04 (1.01–1.08) | 0.021 | ||
MVIVW ‡ | 10 | 1.02 (0.98–1.04) | 10 | 1.04 (1.01–1.15) | ||||
instruments from FADS and genome-wide hits | IVW | 11 | 1.04 (1.02–1.06) | <0.001 | 11 | 1.03 (1.01–1.06) | 0.017 | |
MVIVW | 12 | 1.00 (0.96–1.03) | 0.845 | 12 | 1.03 (0.99–1.06) | 0.108 | ||
MVIVW ‡ | 12 | 1.02 (0.99–1.05) | 12 | 1.04 (0.99–1.07) |
CAD, coronary artery disease; CI, confidence interval; D5D, delta-5-desaturase; D6D, delta-6-desaturase; IVW, inverse variance weighted method; MVIVW, multivariable inverse variance weighted method; OR, Odds ratio; T2DM, type 2 diabetes. * Of the 11/7 SNPs associated with D5D/D6D, 11/7 were available in the GWAS of T2DM [18]. After harmonization and removal of palindromic SNPs with intermediate allele frequencies, 9/6 SNPs were included in the MR analysis on T2DM. For MVMR a combined set of 10 SNPs was used. † Of the 11/7 SNPs associated with D5D/D6D, 10/6 were available in the GWAS of CAD [19]. After harmonization and removal of palindromic SNPs with intermediate allele frequencies, 9/6 SNPs were included in the MR analysis on CAD. For MVMR a combined set of 10 SNPs was used. ‡ adjusting for weak instruments in MVMR, but not for correlation structure between instruments.